John Anderson, MD, talks about the efforts of the American Diabetes Association, and how they are using the successful experiences they have gained through landmark studies such as the Diabetes Prevention Program (DPP), applying this knowledge to new initiatives such as outreach into the community through the YMCA and other …

John Anderson, MD, talks about how clinicians should look at more than just a specific A1c number when beginning treatment for diabetes explaining that the measure is really only a way to project future risk. Factors such as family history, ethnic background and other characteristics may be more relevant. But …

Typically when we have discussions about new drugs or drug classes they are not really discussions but presentations by someone on behalf of the manufacturer, and most of the questions are geared to promote the positive aspects of the new medication. In this month’s special edition covering SGLT-2 inhibitors, we …

We know that obesity can lead to diabetes and often we focus on that in prediabetes, but as soon as someone is diagnosed with diabetes we change our focus to treating diabetes, and "live" with the obesity and weight gain. This week, in the final slides of this series by Dr. …

John Anderson, MD, talks about the new SGLT-2 inhibitors, what he has heard so far on their efficacy, and some of the concerns that have been raised about this new class of drugs…. See more SGLT-2 Resources More videos with John Anderson, MD: John Anderson, MD, ADA Board of Directors, …

Dr. Stanley Schwartz finishes up his slides series on the current state of the obesity epidemic and its relationship with diabetes. Topics covered in this set include a discussion of the newest drug therapies on the market including the incretins and the SGLT-2 inhibitors…. To download in PowerPoint (.ppt) format: Obesity …

Richard S. Beaser, MD This week’s excerpt covers the following topics: Knowing the options for treatment Determining medication selection Clinical markers for the dominant underlying pathophysiology The three stages to glucose patterns

New Global Sugar Intake Guideline Needs Your Input See this week’s Item #1.

Answering Patients Questions on Sugar Substitutes  For your patients who have questions about sugar substitutes, just hand them this simple 1-page handout with straightforward answers. Answering Patients Questions on Sugar Substitutes

Pendiq  The next generation in insulin pens comes to Europe first as they use pens 5-8 times more than the U.S. does. The pen can deliver dosages with a minimum dose of 2.0 units and increments of 0.1Units can be made. The Pendiq insulin pen is operated with common 3ml insulin …